What are triptans, really?
Almost every painkiller you have ever taken was a hand-me-down. Aspirin came out of willow bark chemistry. Opioids came from the poppy. Even the drugs we now use to prevent migraine started life as blood pressure pills, antidepressants and epilepsy medications, repurposed once somebody noticed a side benefit.
Triptans are the exception. They are the first drug class ever built from scratch around the biology of migraine itself.
The story starts in the 1960s and 70s, when researchers kept finding serotonin fingerprints all over migraine attacks. A team at what was then Glaxo, led by Patrick Humphrey, took that clue seriously and spent most of the 1980s hunting for a molecule that would hit one narrow slice of the serotonin receptor family without touching the rest. Sumatriptan came out of that hunt and reached patients around 1991. It changed migraine care more than anything before it.
Today the family has seven members in wide use: sumatriptan (Imitrex, Imigran), rizatriptan (Maxalt), zolmitriptan (Zomig), eletriptan (Relpax), naratriptan (Amerge, Naramig), frovatriptan (Frova) and almotriptan (Axert). They share a mechanism and differ in personality — how fast they land, how long they stay, how they are delivered.
One thing to fix in your head before anything else: a triptan is not a painkiller with the volume turned up. It is a targeted intervention in one specific pain pathway. That distinction explains basically everything else in this article — why they work so well on migraine, why they are useless for a hangover headache, and why a drug that only narrows blood vessels a little bit still comes with a page of cardiac warnings.
How they work — the simple version
Picture a building with a fire alarm panel. Something sets it off — a real spark, a burnt piece of toast, sometimes nothing anybody can identify. The alarm starts screaming, and then it gets stuck in the "on" position. The sprinklers run. Everybody evacuates. The building keeps behaving as if it is on fire for the next twenty hours.
That is roughly a migraine attack. A network centered on the trigeminal nerve — the big sensory nerve serving your face, scalp and the lining around your brain — starts firing pain signals and won't stop. Vessels in that territory dilate. Inflammatory chemicals leak into the tissue around them. Every step feeds the next.
A general painkiller like ibuprofen or acetaminophen is a pair of earplugs. It muffles the noise for everyone in the building. Sometimes that is enough to get through the afternoon. A triptan does something different: it walks up to the panel and enters the shutdown code.
Mechanically, the code has three parts, and they happen simultaneously (Goadsby, Lipton & Ferrari, NEJM, 2002; PMID 11807151):
1. It narrows the over-dilated vessels. There are 5-HT1B receptors sitting on the smooth muscle of intracranial blood vessels. A triptan switches them on, the muscle contracts, and vessels that had swollen open during the attack come back toward normal calibre. For decades this was thought to be the whole story. It isn't — but it is real, and it is also the source of most of the class's side effects.
2. It quiets the nerve itself. 5-HT1D receptors live on trigeminal nerve endings, on the presynaptic side — the sending end. Activate them and the nerve becomes less willing to release its pain-signalling transmitters. The signal doesn't just get muffled downstream; it gets throttled at the source.
3. It shuts off the CGRP tap. This part took the longest to understand and turned out to matter most. Calcitonin gene-related peptide, CGRP, is a small neuropeptide released by trigeminal nerve endings during an attack. It is one of the most powerful vasodilators the human body makes, and it drives the sterile neurogenic inflammation that keeps a migraine going. Triptans reduce CGRP release — a finding that launched the entire modern generation of migraine drugs, the gepants and anti-CGRP antibodies, which attack the same molecule from other angles.
Put together, the effect is not "less pain." It is an attack that stops. In the reference meta-analysis of 53 randomised trials covering more than 24,000 patients, oral triptans consistently outperformed placebo on headache relief at two hours and on sustained freedom from pain, with real differences between individual agents in speed and durability (Ferrari et al., Lancet, 2001; PMID 11728541).
And now the sentence that this whole article exists to deliver: triptans abort attacks; they do not prevent them. They are fire extinguishers, not smoke detectors. There is no version of triptan therapy where taking one every morning keeps migraines away. Prevention is a different pharmacological job done by different drugs — beta-blockers, certain antiepileptics, CGRP antibodies. Confusing the two is not a small mistake, as you will see below.
What else they do to your body, beyond stopping migraine
Once you know the mechanism, the side effect list stops looking arbitrary.
Triptan sensations. Those 5-HT1B receptors that narrow intracranial vessels are not exclusive to your head. There are some on coronary arteries and in peripheral vessels too. So you get a package of odd, hard-to-describe symptoms that headache specialists literally call triptan sensations: pressure or tightness in the chest, heaviness across the neck and shoulders, a squeezing feeling in the jaw or throat. Something in the range of a third to 40% of users report at least one of these, depending on the drug and the study. They typically arrive within minutes to half an hour, last a short while, and go away on their own.
Here is what matters. Cardiac workups in people who get these sensations have overwhelmingly come back clean — the coronary narrowing a triptan produces in a normal artery is on the order of a few percent, nowhere near enough to starve the heart. But "usually benign" is not "always benign," and the first time it happens it is genuinely frightening. More on telling the difference below.
Flushing, tingling, warmth, a strange taste. Same mechanism, different neighbourhood: peripheral vessel tone shifts, sensory nerves get poked, and nasal sprays in particular leave a bitter aftertaste.
Drowsiness and a washed-out feeling. Some of this is the drug, some is the migraine's own postdrome — the flat, foggy day-after that follows an attack whether you treat it or not.
Medication-overuse headache — the one that actually changes your life. This is the most important thing in this section and the least intuitive. Take a triptan often enough and it stops being the solution and becomes the problem. The pain system adapts. Attacks get more frequent. You take more. Eventually you are living with near-daily headache, driven by the drug that used to fix it.
This isn't a theory. Bigal and colleagues followed a large population cohort and tracked who progressed from episodic to chronic migraine over a year. Frequent triptan use was associated with that transition, with risk climbing steeply above roughly 10 treatment days per month (Headache, 2008; PMID 18808500). The international headache classification defines triptan-overuse headache with that same threshold — regular use on 10 or more days a month for over three months.
Which puts you in an uncomfortable spot if your migraines are frequent, and there is only one honest way out: if you need a triptan more than about twice a week, the answer is not a better triptan. It is a preventive strategy — a conversation with a clinician, not a bigger box.
What people usually take with them, and why
NSAIDs. The most established pairing in the class, and the logic is elegant. A triptan handles the neurovascular side of the attack. An NSAID handles the inflammatory side. Different targets, same fire. In a large randomised programme, a fixed combination of sumatriptan with naproxen sodium beat either component alone on two-hour pain relief and on sustained response through 24 hours (Brandes et al., JAMA, 2007; PMID 17405970). That combination is marketed in the US as Treximet, and the EFNS migraine guideline and the American Headache Society consensus statement both list triptan-plus-NSAID as a legitimate option for people who don't get a clean result from monotherapy (Evers et al., Eur J Neurol, 2009; PMID 19708964; Ailani et al., Headache, 2021; PMID 34160823). If you take NSAIDs regularly, the usual stomach-protection questions apply, including whether a PPI belongs in the picture.
Antiemetics. There is a mechanical problem hiding inside a migraine attack: gastric emptying slows down. Your stomach essentially stops moving things along, which means a tablet you swallowed at the start of an attack can sit there unabsorbed while the headache builds. An antiemetic such as metoclopramide, domperidone or prochlorperazine does two useful things at once — it treats the nausea, and it gets your stomach moving again so the triptan can actually be absorbed. This combination appears in most acute migraine protocols, including primary care ones (Gilmore & Michael, Am Fam Physician, 2011; PMID 21302868). Non-oral routes — nasal spray, subcutaneous injection — sidestep the gut problem entirely, which is why they exist.
MAO inhibitors — hard no. Monoamine oxidase inhibitors are an absolute contraindication with most triptans. MAO-A is a major clearance route for several of them, so blocking it stacks up drug levels while loading the serotonin system at the same time. Standard guidance: no triptan during MAOI treatment, and none within two weeks of stopping one.
Ergotamine derivatives — also no. Ergotamine and dihydroergotamine are vasoconstrictors too, from an older era. Stacking them with a triptan stacks the vasoconstriction, and guidelines put a firm minimum window between the two in both directions.
SSRIs and SNRIs — the murky one. In 2006 the FDA issued an advisory about serotonin syndrome when triptans are combined with SSRIs or SNRIs, and it is still on the labels. But the evidence underneath it has always been thin, and the American Headache Society concluded the data do not support prohibiting the combination — plenty of people with both migraine and depression take both, uneventfully. This is a "know the symptoms and talk to your prescriber" situation rather than a rule.
Don't mix two different triptans. Class guidance is one triptan per attack, and no switching to a different one within 24 hours. The vasoconstrictive effects are additive and there is no efficacy payoff.
Red flags — when to call a doctor
Some of these are about the drug. Some are about the headache. Both matter.
- A headache that arrives at full intensity in seconds, or is the worst of your life. A "thunderclap" onset is not a migraine pattern. It is an emergency evaluation — subarachnoid haemorrhage and other structural causes present exactly this way. Do not reach for a triptan; call emergency services.
- New, severe or persistent chest pain or tightness after a triptan, especially with breathlessness, sweating, faintness or pain spreading to the arm, jaw or back: call emergency services and do not take another dose while awaiting assessment. Symptoms alone cannot reliably distinguish a medication sensation from a heart problem.
- Neurological symptoms that outlast the attack. Weakness, numbness, speech trouble or visual loss persisting after the headache resolves needs urgent assessment, not a repeat dose.
- A change in your usual pattern. A new headache after 50, one steadily worsening week over week, one triggered by coughing or exertion, or one with fever, stiff neck or personality change — reasons to be evaluated rather than medicated.
- Hemiplegic migraine or migraine with brainstem aura. Triptans are conventionally avoided here. The risk is theoretical rather than demonstrated, but the reasoning is sound enough that guidelines keep the caution in place.
- Known coronary artery disease, prior heart attack or stroke, peripheral vascular disease, or uncontrolled hypertension. These are contraindications, not cautions. A drug whose job description includes narrowing arteries does not belong in an already-compromised circulation.
- Headache on most days of the month. This isn't an emergency, but it is the flag people ignore for years. If you are treating headaches more often than you are not, the problem has changed shape and needs a different plan.
What people get wrong
"Triptans are just strong painkillers." They are not painkillers at all in the ordinary sense. Give a triptan to someone with a tension-type headache and you will mostly get side effects. The specificity cuts both ways — it is why they are so effective in migraine and so unremarkable in almost everything else. In cluster headache they do work, but that is because cluster involves the same trigeminovascular machinery, not because triptans are broadly analgesic.
"Sumatriptan didn't work for me, so triptans don't work for me." This one costs people years of unnecessary suffering. The seven triptans differ substantially in bioavailability, how fast they peak and how long they last, and a meaningful share of people who fail one respond well to another. Clinical guidance recommends trying two or three different agents, at adequate dose, before writing off the class (Rizzoli, Continuum, 2012; PMID 22868540). Non-response to one triptan is not class failure.
"I'll take one every day so migraines don't start." The single most damaging misconception about this class. Triptans have no preventive effect whatsoever, and daily use is the well-documented route from episodic migraine to chronic daily headache. If you are reaching for one most days, you don't need more triptan — you need prevention.
"Chest tightness after a triptan means I'm having a heart attack." Usually not. Triptan sensations are one of the best-characterised phenomena in headache medicine, and cardiac investigation of people who report them is overwhelmingly normal. Knowing this in advance takes most of the terror out of it. It does not mean you should ignore pain that feels like the real thing — see the red flags above.
"Take it during the aura, before the pain starts." Intuitive, and it turns out not to work. Trials that dosed triptans in the pure aura phase, before any headache, did not show the benefit you would expect — the drug appears to need the headache phase to act on. Current guidance is to take it early in the headache, as soon as pain is clearly present, rather than during aura. (The newer gepants may eventually change this picture; the triptan evidence has not.)
"All triptans are basically the same." Frovatriptan hangs around for over a day; sumatriptan clears in a couple of hours. Some are available as injections and nasal sprays; most are only tablets. Some are built for speed, others for staying power — which is why the long-acting ones show up in discussions of predictable, cyclical attack patterns like menstrual migraine. These differences are the entire reason there are seven of them instead of one.
"If it worked in the first hour, the attack is over." Recurrence within 24 hours is common with the shorter-acting agents, and it is one of the main reasons combination approaches and longer half-life options exist. A returning headache is not the drug failing; it is the drug wearing off before the attack finished.